Diclofenac Potassium and Lefamulin
Determining the interaction of Diclofenac Potassium and Lefamulin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively. No clinically significant differences in the pharmacokinetics of midazolam were observed when administered concomitantly with lefamulin injection. MANAGEMENT: Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:MONITOR: When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively. No clinically significant differences in the pharmacokinetics of midazolam were observed when administered concomitantly with lefamulin injection.
MANAGEMENT: Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: diclofenac
Brand name: Cambia, Cataflam, Voltaren-XR, Zipsor, Zorvolex, Voltaren, Dyloject, also Cambia
Synonyms: Diclofenac, Diclofenac (Systemic)
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Lefamulin (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Diclofenac Potassium-Lefamulin Acetate
- Diclofenac Potassium-Lefamulin Injection
- Diclofenac Potassium-Lefamulin Tablets
- Diclofenac Potassium-Leflunomide
- Diclofenac Potassium-Legatrin PM
- Diclofenac Potassium-Lemtrada
- Lefamulin-Diclofenac Powder Packets
- Lefamulin-Diclofenac Sodium
- Lefamulin-Diclofenac Sodium topical
- Lefamulin-Diclofenac Sodium Topical Solution
- Lefamulin-Diclofenac Tablets
- Lefamulin-Diclofenac topical